Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on
Healthy Postmenopausal Women
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) announced today that Novartis Pharma AG
has launched a Phase I study in postmenopausal women to determine the
safety and tolerability of oral PTH134, a combination of human PTH-1-34 and
the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R)
technology, for the treatment of postmenopausal osteoporosis. The study is
designed to assess the bioavailability profile of increasing doses of
PTH-1-34 combined with different amounts of 5-CNAC administered orally. The
trial is being conducted in Switzerland and is estimated to yield first
interpretable results by the end of the year.
Osteoporosis is a disease associated with a gradual thinning and
weakening of the bones, occurring most frequently in women after menopause.
Thinner and weaker bones are increasingly susceptible to fractures.
Untreated postmenopausal osteoporosis can lead to chronic back pain,
disabling fractures, and lost mobility.
About Emisphere Technologies, Inc.
Emisphere Technologies, Inc. is a biopharmaceutical company that
focuses on a unique and improved delivery of therapeutic molecules using
its Eligen(R) technology. These molecules and compounds could be currently
available or in development. Such molecules are usually delivered by
injection; in many cases, their benefits are limited due to poor
bioavailability, slow on-set of action or variable absorption. The
Eligen(R) technology can be applied to the oral route of administration as
well other delivery pathways, such as buccal, rectal, inhalation,
intra-vaginal or transdermal. The web site is: http://www.emisphere.com.
Safe Harbor Statement Regarding Forward-looking Statements
The statements in this release and oral statements made by
representatives of Emisphere relating to matters that are not historical
facts (including without limitation those regarding the timing or potential
outcomes of research collaborations or clinical trials, any market that
might develop for any of Emisphere's product candidates and the sufficiency
of Emisphere's cash and other capital resources) are forward-looking
statements that involve risks and uncertainties, including, but not limited
to, the likelihood that future research will prove successful, the
likelihood that any product in the research pipeline will receive
regulatory approval in the United States or abroad, the ability of
Emisphere and/or its partners to develop, manufacture and commercialize
products using Emisphere's drug delivery technology, Emisphere's ability to
fund such efforts with or without partners, and other risks and
uncertainties detailed in Emisphere's filings with the Securities and
Exchange Commission, including those factors discussed under the caption
"Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. 1-10615)
filed on March 17, 2008 and our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2008, filed on May 7, 2008.
SOURCE Emisphere Technologies, Inc.
 back to top
Related links:
http://www.emisphere.com/
CONTACT:
Bob Madison, Senior Director Corporate
Communications of Emisphere Technologies, Inc., +1-973-532-8001;
or Adam Friedman of Adam Friedman Associates, +1-212-981-2529,
ext. 18, for Emisphere Technologies, Inc.
|
